Citations

Clear

2303 citation(s) found for "Yu, Edward".

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey
Hurley, Patricia A. , Kim, Edward S. , Nowakowski, Grzegorz S. , Schilsky, Richard L. , Hurley, Patricia , Waterhouse, David , Harvey, R. Donald , Levit, Laura A. , Klepin, Heidi D. , Mileham, Kathryn Finch , Schenkel, Caroline , Davis, Courtney , Bruinooge, Suanna S.

Mayo Clinic

JCO Oncology Practice | May 12, 2020 | Volume: 16 | Issue: 7 | Pages: 417-421

10.1200/op.20.00275 | PMID 32396491 Get It

The coronavirus disease 2019 (COVID-19) pandemic has disrupted all aspects of clinical care, including cancer clinical trials. In March 2020, ASCO launched a survey of clinical programs represented on its Cancer Research Committee and Research Community Forum Steering Group and taskforces to learn about the types of changes and challenges that clinical trial programs were experiencing early in the pandemic. There were 32 survey respondents; 14 represented academic programs, and 18 represented community-based programs. Respondents indicated that COVID-19 is leading programs to halt or prioritize screening and/or enrollment for certain clinical trials and cease research-only visits. Most reported conducting remote patient care where possible and remote visits and monitoring with sponsors and/or contract research organizations (CROs); respondents viewed this shift positively. Numerous challenges with conducting clinical trials were reported, including enrollment and protocol adherence difficulties with decreased patient visits, staffing constraints, and limited availability of ancillary services. Interactions with sponsors and CROs about modifying trial procedures were also challenging. The changes in clinical trial procedures identified by the survey could serve as strategies for other programs attempting to maintain their clinical trial portfolios during the COVID-19 pandemic. Additionally, many of the adaptations to trials made during the pandemic provide a long-term opportunity to improve and transform the clinical trial system. Specific improvements could be expanded use of more pragmatic or streamlined trial designs, fewer clinical trial–related patient visits, and minimized sponsor and CRO visits to trial programs.
Survival following allogeneic transplant in patients with myelofibrosis
Gowin, Krisstina , Ballen, Karen K. , Ahn, Kwang Woo , Hu, Zhen‐Huan , Ali, Haris , Arcasoy, Murat O. , Devlin, Rebecca, Coakley, Maria , Gerds, Aaron T. , Jain, Tania , Kandarpa, Malathi , Komrokji, Rami S. , Luber, Kierstin, Michaelis, Laura C. , Patches, Sarah, Pariser, Ashley, Rampal, Raajit K. , Stein, Brady L. , Verstovšek, Srđan , Wadleigh, Martha , Aljurf, Mahmoud , Avalos, Belinda R. , Bashey, Asad, Beitinjaneh, Amer , Černý, Jan , Copelan, Edward A. , DeFilipp, Zachariah , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hashmi, Shahrukh K. , Kharfan‐Dabaja, Mohamed A. , Kindwall‐Keller, Tamila L. , Kröger, Nicolaus , Litzow, Mark R. , Marks, David I. , Nathan, Sunita , Pawarode, Attaphol , Rowe, Jacob M. , Savoie, Mary Lynn , Seo, Sachiko , Solh, Melhem , Tamari, Roni , Verdonck, Leo F. , Alyea, Edwin P. , Sobecks, Ronald , Scott, Bart L. , Nakamura, Ryotaro , Saber, Wael , Kroger, Nicolaus , Davenport, Ashley Pariser , Gerds, Aaron T , Jain, Tania , Gadalla, Shahinaz M , Verstovsek, Srdan , Komrokji, Rami S , Kroger, Nicolaus , Kröger, Nicolaus , Green, Michael, Gupta, Vikas , Hobbs, Gabriela , Kuykendall, Andrew , Masárová, Lucia , Talpaz, Moshe , Agrawal, Vaibhav , Díaz, Miguel Ángel , Bacher, Ulrike , Chhabra, Saurabh , Cutler, Corey S. , Grunwald, Michael R. , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Olsson, Richard F. , Savani, Bipin N. , Yared, Jean A. , Popat, Uday R , Mesa, Ruben A.

Mayo Clinic

Blood Advances | May 8, 2020 | Volume: 4 | Issue: 9 | Pages: 1965-1973

10.1182/bloodadvances.2019001084 | PMID 32384540 Get It

Abstract Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.
Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States
Raffals, Laura H., Long, Millie D. , Syal, Gaurav , Kayal, Maia , Cohen, Benjamin L., Deepak, Parakkal , Sandler, Robert S. , Raffals, Laura, Kayal, Maia , Deepak, Parakkal , Sandler, Robert S , Barnes, Edward L. , Ananthakrishnan, Ashwin N. , Pekow, Joel , Colombel, Jean‐Frédéric , Herfarth, Hans

Mayo Clinic

Crohn's & Colitis 360 | May 8, 2020 | Volume: 2 | Issue: 3 | Pages: No page available

10.1093/crocol/otaa039 | PMID 32744536 Get It

AbstractBackgroundGaps exist in our understanding of the clinical course of pouch-related disorders.MethodsWe evaluated baseline disease activity and longitudinal treatment patterns among patients with inflammatory conditions of the pouch.ResultsAmong 468 patients with an ileal pouch-anal anastomosis (IPAA), 94 (20%) had acute pouchitis, 96 (21%) had chronic pouchitis, and 192 (41%) had Crohn disease of the pouch. Following an IPAA, 38% of patients were treated with a biologic and 11% underwent inflammatory bowel disease- or bowel-related surgery.ConclusionsTreatment patterns after IPAA indicate that pouch-related disorders have a significant impact on individual patients and the healthcare system.
SUN-344 Patients with Fibrodysplasia Ossificans Progressiva Have an Increased Prevalence of Cardiac Conduction Abnormalities
Kou, Samuel , DeCunto, Carmen, Wentworth, Kelly L. , Grogan, Donna R., Rocco, Maja Di , Mukaddam, Mona Al , Kaplan, Frederick S. , Pignolo, Robert J. , Kaplan, Frederick S , Baujat, Geneviève , Brown, Matthew A. , Keen, Richard , Hsiao, Edward C.

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.238 Get It

Abstract Background Genetic contributors to cardiac arrhythmias often found in cardiovascular conduction pathway and channel proteins. However, genes outside of these categories can contribute to cardiovascular conduction abnormalities. Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by large volumes heterotopic ossification caused by a highly recurrent R206H mutation in the ACVR1/Alk2 gene. This mutation produces an abnormal activation of the bone morphogenetic pathway (BMP) pathway in response to Activin A. Prior studies suggested an increased risk of cardiopulmonary complications in FOP1. We examined patients in a Natural History Study (NHS) of FOP (NCT02322255) to better understand their cardiovascular risk. Methods The NHS is an ongoing 3 year international multi-center cross-sectional study of 114 patients with FOP (ages 4–56 years) genetically verified to have the AVCR1 R206H mutation. Patients at baseline and 12 months were assessed by electrocardiogram (ECG). Abnormal lead placements were excluded. ECG readings were assessed in a central ECG laboratory. Results At baseline, 45.3% (48/106) of ECGs showed conduction abnormalities. The majority of these abnormalities were classified as nonspecific intraventricular conduction delay (37.7% of all ECGs). For patients > 18 years old, 22.7% (10/44) had conduction abnormalities, which was significantly higher than previously reported in the healthy population (5.9%; n=3978)2 (proportional t-test; p<0.00001). FOP patients < 18 years of age also had an extremely high prevalence of conduction abnormalities (60.3%, 38/61). The NHS 12-month follow up data showed similar prevalence. The high frequency of conduction abnormalities did not correlate with the presence of chest wall deformities or scoliosis, abnormal pulmonary function test results, increased cumulative analog joint involvement scale (CAJIS) scores, or abnormal echocardiograms. Conclusions Our results show that some patients with FOP may have subclinical conduction abnormalities. These ECG changes appear to be independent of chest wall deformities or scoliosis, although ectopic bone may make ECG measurement in FOP patients challenging. Though there is no reported association of FOP with clinically significant heart block to date and clinical implications for cardiovascular risk remain unclear, knowledge about these ECG changes may be important for planning clinical care and clinical trials of investigational agents in patients with FOP. Further studies of how the AVCR1 R206H activating mutation and BMP signaling changes cardiac conduction are needed to better understand the mechanistic link. References (1)Hingorani et al. Indian J Med Res. 2012; 135:322–330 (2)Kussmaul et al. Clinical Orthopaedic Related Research. 1998; 346:104–109
OR29-05 A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes
Mukaddam, Mona Al , Pignolo, Robert J. , Cunto, Carmen De , Rocco, Maja Di , Strahs, Andrew , Marino, Rose , Kaplan, Frederick S. , Kaplan, Frederick S , Baujat, Geneviève , Brown, Matthew , Hsiao, Edward C. , Keen, Richard , Sang, Kim‐Hanh Le Quan

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.254 Get It

Abstract Background: FOP is an ultra-rare, severely disabling genetic disorder characterized by episodic flare-ups and heterotopic ossification (HO) leading to restricted movement, physical disability, and early death. FOP may initially be misdiagnosed in ~90% of individuals leading to unnecessary and often harmful interventions. Patients with FOP are diagnosed and managed by multiple specialties, including endocrinologists. Data from an ongoing, prospective, longitudinal, global, natural history study (NCT02322255) were used to investigate the progression of FOP, HO formation, and impact on physical functioning over time. We present results from the first 12 months of the 3-year study. Methods: Males and females with FOP and a documented ACVR1 R206H mutation participated. HO volume was assessed by low-dose whole body computed tomography (WBCT) scan, excluding the head. All imaging was interpreted at a blinded, central laboratory using pre-specified procedures. Functional outcomes were evaluated using the Cumulative Analogue Joint Involvement Scale (CAJIS; for each joint: score=0 represents <10% involvement, score=1 represents 10–90% involvement, and score=2 represents >90% ankylosed across 15 major joints; total score range 0 to 30 [higher scores indicate more severe mobility limitations]) and the FOP Physical Function Questionnaire (FOP-PFQ; percent total score). Changes from Baseline at Month 12 were evaluated for new HO volume, CAJIS, and FOP-PFQ. Results: Of 114 participants (pts) with Baseline data, 99 (4 to 56 years at enrollment; mean 17 years of age; 56% male) also had a Month 12 assessment. A total of 93 pts had evaluable WBCT scans at Baseline and Month 12 and were included in the HO analysis. In total, 40% (37/93) of pts had new HO over 12 months; the mean volume of new HO in these pts was 57,706 mm3 (SD=100,079 mm3; median=20,753 mm3; range: 522 to 438,826 mm3). Of the pts with new HO, 65% (24/37) reported at least one flare-up (mean rate of 2.3 flare-ups/year). Over 12 months, 60% (56/93) of pts did not have new HO; 43% (24/56) of them reported at least one flare-up (mean rate of 1.8 flare-ups/year). Mean changes from Baseline in CAJIS and FOP-PFQ were minimal: CAJIS: 0.6 (SD=2.4; median=1.0; n=99) and FOP-PFQ: 4.4% (SD=11.2; median=3.7%; n=90); and were similar across pts with or without new HO. Conclusions: In participants with FOP, although deterioration of physical function is expected over a patient’s lifetime, CAJIS and FOP-PFQ scores did not worsen significantly in the relative short-term of this study. However, HO volume, quantified by WBCT, increased over the course of 12 months. These results show that measuring HO may be a viable way to monitor changes in FOP over short periods of time.
PWE-047 Improved patient-reported outcomes with upadacitinib over 52 weeks in patients with moderate-to-severe crohn’s disease
Louis, Édouard , Cataldi, Fabio, Lacerda, Ana P. , Peyrin‐Biroulet, Laurent , Louis, Edouard , Loftus, Edward V. , Lee, Wen‐Jeng , Ghosh, Subrata

Mayo Clinic

Posters | May 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: A195.1-A195

10.1136/gutjnl-2019-bsgabstracts.371 Get It

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS—2020 UPDATE EXECUTIVE SUMMARY
Camacho, Pauline M., Petak, Steven M., Binkley, Neil , Diab, Dima L., Eldeiry, Leslie S. , Harris, Steven T. , Hurley, Daniel L. , Pessah‐Pollack, Rachel , Watts, Nelson B. , Farooki, Azeez , Kelly, Jennifer, Lewiecki, Edward Michael , McClung, Michael R. , Wimalawansa, Sunil J.

Mayo Clinic

Endocrine Practice | April 27, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.4158/gl-2019-0524 Get It

Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPG). Methods: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols. Results: The Executive Summary of this 2020 updated guideline contains 52 recommendations: 21 Grade A (40%), 24 Grade B (46%), 7 Grade C (14%), and no Grade D (0%). These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients. The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations. This update contains 368 citations: 123 (33.5%) EL 1 (highest), 132 (36%) EL 2 (intermediate), 20 (5.5%) EL 3 (weak), and 93 (25%) EL 4 (lowest). New or updated topics in this CPG include: clarification of the diagnosis of osteoporosis, stratification of the patient according to high-risk and very high-risk features, a new dual action therapy option, and transitions from therapeutic options. Conclusion: This guideline is a practical tool for endocrinologists, physicians in general, regulatory bodies, health-related organizations, and interested laypersons regarding the diagnosis, evaluation, and treatment of postmenopausal osteoporosis.
Risk of de‐novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications
Kochhar, Gursimran , Syed, Aslam , Grover, Abhinav , Hachem, Sandra El, Abdul‐Baki, Heitham, Chintamaneni, Preethi, Aoun, Elie, Kanna, Sowjanya, Sandhu, Dalbir S. , Singh, Siddharth , Shen, Bo , Loftus, Edward V. , Dulai, Parambir S. , Kochhar, Gursimran S , Singh, S , Loftus, Edward V , Dulai, Parambir S , Desai, Aakash

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 22, 2020 | Volume: 51 | Issue: 11 | Pages: 1067-1075

10.1111/apt.15721 | PMID 32319111 Get It

SummaryBackgroundAn association between bariatric surgery and development of de‐novo inflammatory bowel disease (IBD) has been observed.AimTo evaluate further the association among bariatric surgery, weight loss medications, obesity and new‐onset IBD.MethodsUsing Explorys, a population‐based Health Insurance Portability and Accountability Act compliant database, we estimated the prevalence of de‐novo IBD among patients treated with bariatric surgery (Roux‐en‐Y gastrojejunostomy, laparoscopic sleeve gastrectomy or gastric banding) (n = 60 870) or weight loss medications (orlistat, phentermine/topiramate, lorcaserin, bupropion/naltrexone and liraglutide) (n = 193 790) compared with obese controls (n = 5 021 210), between 1999 and 2018.ResultsThe prevalence of de‐novo IBD was lower among obese patients exposed to bariatric surgery (7.72 per 1000 patients) or weight loss medications (7.22 per 1000 patients) compared with patients with persistent obesity not exposed to these interventions (11.66 per 1000 patients, P < 0.0001). The risk reduction for de‐novo IBD was consistent across bariatric surgeries and weight loss medications with the exception of orlistat which was not associated with a reduction in risk for de‐novo IBD compared with the persistent obese control cohort.ConclusionObese patients undergoing treatment with bariatric surgery or weight loss medications are at a lower risk for developing de‐novo IBD compared with persistently obese controls not exposed to these interventions. These data suggest that obesity and ineffective management of obesity are risk factors for de‐novo IBD. Further research is needed to confirm these observations and understand potential mechanisms.
International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) Study on Low-Grade Primary Central Nervous System Lymphoma in Immunocompetent Patients.
Korfel, Agnieszka, Jahnke, Kristoph, Abrey, Lauren E. , Poortmans, Philip , Shenkier, Tamara , Batchelor, Tracy T. , Neuwelt, Edward A. , Raizer, Jeffrey J. , Pels, Hendrik, Herrlinger, Ulrich , Thiel, Eckhard, O’Neill, Brian Patrick , Blay, Jean‐Yves , Martus, Peter

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 3343-3343

10.1182/blood.v106.11.3343.3343 Get It

Abstract Low-grade primary central nervous system lymphoma is a very rare subtype of primary central nervous system lymphoma (PCNSL), for which almost no data is currently available. The purpose of this retrospective study was to characterize the clinical presentation, course and outcome of patients with low-grade PCNSL. Forty patients (18 male, 22 female) from 18 cancer centers in five countries were identified with a median age of 58 (range, 19–78) years and a median Eastern Cooperative Oncology Group (ECOG) performance status of 1 (range, 0–4). The mean time to diagnosis was 14.8 months (range, 0.25–84). Thirty-two patients (80%) had a B-cell and eight a T-cell lymphoma. Thirty-seven patients (92.5%) showed involvement of a cerebral hemisphere or deeper brain structures, while two evidenced only leptomeningeal involvement, and one patient had spinal cord disease. Treatment was performed in 39 patients: chemotherapy and radiotherapy in 15 (38%), radiotherapy alone in 12 (30%), chemotherapy alone in 10 (25%), and tumor resection alone in two. The median progression-free survival (PFS), disease-specific survival (DSS) and overall survival (OAS) were 61.5 (range, 0–204), 130 (range, 1–204), and 79 (range, 1–204) months, respectively. An age ≥60 years was associated with a shorter PFS (P = .009), DSS (P = .015) and OAS (P = .001) in multivariate analysis. Low-grade PCNSL differ from the high-grade subtype in pathological, clinical and radiological features. In this study, the long-term outcome was better as compared to the results obtained in PCNSL in general with age ≥60 years adversely affecting survival.